Unaudited Financial Results for the Quarter ended June 30, 2026

INDGN/SE/2026-27/35 30 July 2026 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Madam, Subject: Outcome of Board Meeting held on July 30, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that the Board of Directors of Indegene Limited at its meeting held on Thursday, July 30, 2026, has, inter alia: 1. Approved unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Auditors thereon for the quarter ended June 30, 2026. The Financial Results along with the Limited Review Report of the Auditors with an unmodified opinion and CFO declaration are enclosed herewith. 2. Approved allotment under ESOP Scheme 2020. Please be informed that pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 and the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading Window for dealing in the securities of the Company by its Designated Persons shall reopen with effect from Monday, 03rd August, 2026. The meeting of the Board of Directors commenced at 05:30 PM (IST) and concluded at 06:15 PM (IST). The above information will be made available on the website of the Company: https://www.indegene.com/ We request you to kindly take the same on record. Thanking You Yours Sincerely, For Indegene Limited Srishti Ramesh Kaushik Company Secretary and Compliance Officer Encl: A/a Indegene Limited Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India Phone: +91 80 4674 4567, +91 80 4644 7777 compliance.officer@indegene.com www.indegene.com CIN: L73100KA1998PLC102040 Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds, Bengaluru – 560 001 Karnataka, India Tel: +91 (80) 6188 6000 Fax: +91 (80) 6188 6011 INDEPENDENT AUDITOR’S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF INDEGENE LIMITED 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of INDEGENE LIMITED (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), for the quarter ended June 30, 2026 (“the Statement”) being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”). 2. This Statement, which is the responsibility of the Parent’s Management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. The Statement includes the results of the entities as mentioned in Annexure I to this review report. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. The consolidated unaudited financial results includes the interim financial information of 1 subsidiary and 10 step down subsidiaries which have not been reviewed by their auditors, whose interim financial information reflects total revenue of Rs. 413 million for the quarter ended June 30, 2026, total loss after tax of Rs. 12 million for the quarter ended June 30, 2026 and other comprehensive loss of Rs. 18 million for the quarter ended June 30, 2026, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management. For Deloitte Haskins & Sells Chartered Accountants Firm’s Registration No. 008072S Sathya P Koushik Partner Membership No.: 206920 UDIN: 26206920XKSBYL3444 Place: Bengaluru Date: July 30, 2026 Annexure I to Independent Auditor’s Review Report on Review of Interim Consolidated Financial Results. The Consolidated Unaudited Financial Results for the quarter ended June 30, 2026 include financial results of the following companies: Sr. Company Name Category Country of No. Incorporation 1 Indegene Limited Parent Company India 2 ILSL Holdings Inc. Wholly Owned Subsidiary USA 3 Indegene Inc. Step Down Subsidiary USA 4 Indegene Healthcare Canada Inc. Step Down Subsidiary Canada 5 DT Associates Research and Consulting Step Down Subsidiary England Services Ltd 6 DT Associates Research and Consulting Step Down Subsidiary USA Inc. 7 Cult Health LLC Step Down Subsidiary USA 8 Indegene Japan LLC Step Down Subsidiary Japan 9 Indegene Healthcare Mexico S DE RL DE Wholly Owned Subsidiary Mexico 10 Indegene Ireland Limited Wholly Owned Subsidiary Ireland 11 Indegene Healthcare Germany GmbH Step Down Subsidiary Germany 12 Indegene Fareast Pte Ltd Step Down Subsidiary Singapore 13 Indegene Europe LLC Step Down Subsidiary Switzerland 14 Indegene Lifesystems Consulting Step Down Subsidiary China (Shanghai) Co. Ltd. 15 Indegene Healthcare UK Limited Step Down Subsidiary England 16 Trilogy Writing & Consulting GmbH Step Down Subsidiary Germany 17 Trilogy Writing & Consulting Limited Step Down Subsidiary England 18 Trilogy Writing & Consulting Inc. Step Down Subsidiary USA 19 Indegene Spain S.L.U Step Down Subsidiary Spain 20 MJL Communications Group Ltd Step Down Subsidiary England 21 MJL Advertising Limited Step Down Subsidiary England 22 BioPharm Parent Holding, Inc Step Down Subsidiary USA 23 BioPharm Communications LLC Step Down Subsidiary USA 24 Addressable Health LLC Step Down Subsidiary USA 25 Warn and Co Limited Step Down Subsidiary England 26 Cake Kommunikations Holding GmbH Step Down Subsidiary Austria 27 Cake Kommunikations GmbH (AT) Step Down Subsidiary Austria 28 CAKE Kommunikations AG Step Down Subsidiary Switzerland 29 Cake Kommunikations GmbH (DE) Step Down Subsidiary Germany Page 2 of 2 INDEGENE LIMITED I CIN No. L73100KA1998PLC102040 Statement of Consolidated Finan [Showing first 8,000 characters — download PDF for full document]